CN102796093B - Thiomorpholine-containing pyrrole derivatives and their preparation method and use - Google Patents
Thiomorpholine-containing pyrrole derivatives and their preparation method and use Download PDFInfo
- Publication number
- CN102796093B CN102796093B CN201210301823.9A CN201210301823A CN102796093B CN 102796093 B CN102796093 B CN 102796093B CN 201210301823 A CN201210301823 A CN 201210301823A CN 102796093 B CN102796093 B CN 102796093B
- Authority
- CN
- China
- Prior art keywords
- compound
- acceptable salt
- pharmacy acceptable
- preparation
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *C(*1)NCCSC1=N Chemical compound *C(*1)NCCSC1=N 0.000 description 2
- OKHMEOHCPHVQBF-UHFFFAOYSA-N CC(c1c(C)[n](C2CC2)c(C)c1C(Cl)=O)=O Chemical compound CC(c1c(C)[n](C2CC2)c(C)c1C(Cl)=O)=O OKHMEOHCPHVQBF-UHFFFAOYSA-N 0.000 description 2
- PMHYMFUAVMMOOR-UHFFFAOYSA-N CC(c1c(C)[n](C2CC2)c(C)c1C(N1CSCC1)=O)=O Chemical compound CC(c1c(C)[n](C2CC2)c(C)c1C(N1CSCC1)=O)=O PMHYMFUAVMMOOR-UHFFFAOYSA-N 0.000 description 1
- JSEIYOKZAHNTFI-UHFFFAOYSA-N CC(c1c(C)[n](C2CC2)c(C)c1C(O)=O)=O Chemical compound CC(c1c(C)[n](C2CC2)c(C)c1C(O)=O)=O JSEIYOKZAHNTFI-UHFFFAOYSA-N 0.000 description 1
- GKTWGGQPFAXNFI-UHFFFAOYSA-N COC(C(c(cccc1)c1Cl)N(CC1)Cc2c1[s]cc2)=O Chemical compound COC(C(c(cccc1)c1Cl)N(CC1)Cc2c1[s]cc2)=O GKTWGGQPFAXNFI-UHFFFAOYSA-N 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N Clc1c(CN(CC2)Cc3c2[s]cc3)cccc1 Chemical compound Clc1c(CN(CC2)Cc3c2[s]cc3)cccc1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of antiplatelet drugs and provides thiomorpholine-containing pyrrole derivatives and pharmaceutically acceptable salts thereof. The thiomorpholine-containing pyrrole derivatives have a general structural formula I. In the general structural formula I, m and R are defined in the patent specification. The invention relates to a preparation method of the thiomorpholine-containing pyrrole derivatives, discloses a drug composition containing the thiomorpholine-containing pyrrole derivatives or their pharmaceutically acceptable salts as active ingredients, and also discloses a use of the thiomorpholine-containing pyrrole derivatives and their pharmaceutically acceptable salts in antiplatelet drugs.
Description
Technical field
The invention belongs to medical art, or rather, relate to class compound with antiplatelet aggregative activity and preparation method thereof, containing their pharmaceutical composition and the purposes as antiplatelet drug.
Background technology
In rising trend based on the sickness rate of the thrombotic disease of coronary artery thrombus and cerebral thrombosis in recent years, serious harm human health.Platelet aggregation is a key link in normal coagulation mechanism, and hematoblastic adhesion, gathering, release reaction cause thrombosis.Therefore anticoagulant medicine plays a significant role in treatment thrombus disease, is the focus that people study always.
Clinically, acetylsalicylic acid is as medicament for resisting platelet aggregation widespread use.Although acetylsalicylic acid can tolerate by most people, even but sometimes low dose also may cause part population gastrointestinal discomfort, even serious gastrointestinal hemorrhage or hematencephalon, have also appeared Aspirin Resistance in recent years.
The important agonist that adenosine diphosphate (ADP) (ADP) is platelet activation, buildup effect is amplified, suppresses Platelet to become the important means stoping pathologic thrombus to form (coronary heart disease, cerebro-vascular diseases, pulmonary infarction, thrombophlebitis etc.) and myocardial infarction, unstable angina pectoris, peripheral vascular disease, congestive heart failure etc. by blocking adp receptor.Adp receptor antagonist Ticlopidine (Ticlopidine) is first thienopyridine medicine, develops listing by French Sanofi company.It is by being combined with the special thiol acceptor of P2Y type, suppresses the activation of adp receptor.By changing the interaction of platelet membrane and interference membrane fiber proteinogen, glycoproteinⅱb/ⅲa acceptor on blocking platelet film, suppressing the platelet aggregation of being induced by ADP and other platelet activating agents to react, is a kind of effect medicament for resisting platelet aggregation stronger than acetylsalicylic acid.Because Ticlopidine not only suppresses a certain platelet aggregation incitant, and inhibit accumulation process itself, applied widely in clinical.Especially at prevention cerebral infarction, treat stenocardia, prevent and treat myocardial infarction and improve in peripheral vascular occlusive disease etc. evident in efficacy.But the side effects such as Ticlopidine can cause Neutrophilic granulocytopenia, thrombopenia, bone marrow depression, hinders, thrombotic thrombocytopenic purpura (TTP).
Clopidogrel (Clopidogrel) is second thienopyridine medicine of French Sanofi company development, compared with Ticlopidine, only many carboxymethyls on side chain in structure, its action intensity and tolerance are all higher than Ticlopidine, and only anti-platelet activity is just high than Ticlopidine 6 times.Be applied to treatment atheromatosis clinically, acute coronary syndrome, prevention intracoronary stent plant restenosis and thrombotic complications etc. in people's postoperative support.In June, 1998, Britain went on the market, and August calendar year 2001 goes on the market in China in the U.S..In multinomial broad scale research, clopidogrel, in the prognosis improving ischemic events, is better than other drug, and ADR is few compared with Ticlopidine, and security is better than acetylsalicylic acid, and thus clopidogrel instead of the application of Ticlopidine in many cases.But accept Effect of Clopidogrel in Treating and also occurred TTP and hemolytic uremic syndrome (HUS), simultaneously about the report of clopidogrel Resistant also had increase in recent years.Because clopidogrel is oily matter, alkalescence is extremely weak, need could salify with strong acid, but it is unstable to meet moisture, and free alkali is separated out, and purifying also has certain difficulty.And due to its strongly-acid, in preparation, receive certain restriction.
Therefore, one of more safe and effective Novel anti-platelet agent thing study hotspot becoming researcher is found.
Summary of the invention
One object of the present invention is, in order to solve the problem of clopidogrel Resistant, develops pyrrole derivative and the pharmaceutical salts thereof of a kind of novel sulfurized generation morpholine.
Another object of the present invention is, discloses the pyrrole derivative of novel sulfurized generation morpholine and the preparation method of pharmaceutical salts thereof.
Another object of the present invention is, the pyrrole derivative and the pharmaceutical salts thereof that disclose novel sulfurized generation morpholine are the pharmaceutical composition of main active ingredient.
A further object of the invention is, disclose pyrrole derivative and the pharmaceutical salts thereof of novel sulfurized generation morpholine, as the application of antiplatelet drug aspect, particularly at the coronary syndrome caused because of platelet aggregation for the preparation of prevention or treatment, myocardial infarction, myocardial ischemia, the purposes of cardiovascular and cerebrovascular diseases medicament aspect.
Known through Preliminary pharmacological test, the compounds of this invention all has superiority to a certain degree compared with clopidogrel in drug effect and acute toxicity two.
Now in conjunction with the object of the invention, content of the present invention is described in detail.
The present invention is specifically related to compound and the pharmacy acceptable salt thereof of formula I structure:
Wherein:
m＝0，1；
R is: hydrogen, C
1-C
4alkyl.
Preferred following compound and pharmacy acceptable salt thereof:
Wherein:
m＝0，1；
R is: hydrogen, methyl.
More preferably following compound and pharmacy acceptable salt thereof:
I-11-(1-cyclopropyl-2,5-dimethyl-4-(thiazolidine-3-carbonyl)-1H-pyrroles-3-base) ethyl ketone;
I-21-(1-cyclopropyl-2,5-dimethyl-4-(2-methylthiazol alkane-3-carbonyl)-1H-pyrroles-3-base) ethyl ketone;
I-31-(1-cyclopropyl-2,5-dimethyl-4-(thiomorpholine-4-carbonyl)-1H-pyrroles-3-base) ethyl ketone.
Generalformulaⅰcompound pharmacy acceptable salt refers to: compound and mineral acid, organic acid salify; With oxide compound, the oxyhydroxide salify of basic metal, alkaline-earth metal.Wherein preferred: hydrochloride, hydrobromate, hydriodate, vitriol, hydrosulfate, phosphoric acid salt, acetate, propionic salt, butyrates, lactic acid salt, mesylate; tosilate, maleate, benzoate, succinate, tartrate, Citrate trianion, fumarate, taurate etc.
The syntheti c route of type I compound is as follows:
4-ethanoyl-1-cyclopropane-2,5-dimethyl-1H-pyrroles-3-carboxylic acid (II), refluxes in thionyl chloride, and reaction generates intermediate III.Intermediate III and compound 2 are at methylene dichloride, trichloromethane, acetone, N, in dinethylformamide or toluene equal solvent, with under the catalysis of the acid binding agents such as triethylamine, pyridine, salt of wormwood, sodium carbonate, sodium bicarbonate, saleratus, sodium hydroxide or potassium hydroxide ,-10 ~ 30 DEG C of reacting generating compounds I.
The obtained various compound of reaction or products therefrom is dissolved in DMF, acetone, methyl alcohol, ethanol or DMSO drip mineral acid, pharmacy acceptable salt made by organic acid.
Specifically products therefrom is dissolved in DMF, acetone, methyl alcohol, ethanol or DMSO, drips acidic alcohol to pH2, make hydrochloride.Or products therefrom is dissolved in DMF, acetone, methyl alcohol or ethanol, the molar lactic acid such as to add, obtain its lactic acid salt.
The disease that this compounds causes because of platelet aggregation for the treatment mankind is effective.Although compound of the present invention can without the direct administration of any preparation, described various compounds preferably use in the form of a pharmaceutical preparation, and route of administration can be parenteral route (as vein, intramuscular delivery) and oral administration.
The pharmaceutical composition of the compounds of this invention is prepared as follows: use standard and conventional technology; the compounds of this invention acceptable solid or liquid vehicle on technology of pharmaceutics are combined, and make it at random on technology of pharmaceutics acceptable auxiliary and vehicle be combined and be prepared into particulate or microballoon.Solid dosage comprises tablet, discrete particles, capsule, slow releasing tablet, sustained release pellet etc.Solid carrier can be at least one material, and it can serve as thinner, flavouring agent, solubilizing agent, lubricant, suspension agent, tackiness agent, disintegrating agent and coating agent.Inert solid carrier comprises trimagnesium phosphate, Magnesium Stearate, smoothers sugar, lactose, pectin, propylene glycol, Polysorbate 80, dextrin, starch, gelatin, cellulose substances such as methylcellulose gum, Microcrystalline Cellulose, low melt point paraffin, polyoxyethylene glycol, N.F,USP MANNITOL, theobroma oil etc.Liquid dosage form comprises solvent, suspension such as injection, pulvis etc.
The amount of the active ingredient (the compounds of this invention) contained in pharmaceutical composition and unit dosage form specifically can be applied according to the situation of the state of an illness of patient, diagnosis, and the amount of compound used or concentration regulate in a wider scope.Usually, the weight range of active compound is 0.5 ~ 90% (weight) of composition, and another preferred scope is 0.5 ~ 70%.
Compound or its pharmacy acceptable salt with structure shown in formula I of the present invention, has obvious restraining effect in platelet aggregation.
The antithrombotic acitivity of the compounds of this invention is further illustrated below by pharmacodynamic experiment.
A. to rat platelet aggregation restraining effect
Medicine and preparation: compound is made into suspension for animals administer with 0.5%CMC; Adenosine diphosphate (ADP) (ADP) (SERVA company, lot number 01993).
Animal: male rat, Tianjin Inst. of Materia Medica laboratory animal room provides, animal conformity certification number: No. 001st, Tianjin animal word.
Instrument: PK121R type whizzer (Italian ALC International SPL product), SPA-3 type PPP platelet aggregation instrument (Shanghai Kodak testing tool factory).
Test method: male Wistar rat, about body weight 300g, per os gavage gives Clopidogrel Hydrogensulfate and analogue thereof, and dosage is 10mg/kg, administration volume is 10ml/kg, after 2h, etherization, aorta abdominalis is taken a blood sample, 3.8% Sodium Citrate anti-freezing, whole blood is the centrifugal 7min of 9:1,1000rpm with the ratio of antithrombotics, prepares platelet rich plasma (PPP).Adjust PRP with PPP, make its platelet count remain on 2 × 106/ml.Getting PRP adds in test cup, and 37 DEG C of temperature incubate 10min.With PRP zeroing, PPP adjusts 100%, with ADP (final concentration is 5 μMs) for inductor, measures platelet aggregation percentage ratio by turbidimetry SPA-3 type PPP platelet aggregation instrument, carries out statistics compare with t-inspection.The results are shown in Table 1.
Table 1 pair rat platelet aggregation restraining effect
B.ADP causes mouse brain embolism model
Medicine and preparation: tween 80 (Tianjin fine chemicals company limited), lot number: 920311.ADP (the biological engineering finite leading company of astronomical phenomena people).Clopidogrel (portion provides by chemical pharmacy), lot number 080516.
Animal: ICR mouse, male and female dual-purpose, by animal housing of the court propagating and breeding.
Test method: animal successive administration 3 days, route of administration is abdominal injection, and dosage is 100mg/kg.Model group gives the physiological saline with the capacity of grade.In last administration tail vein injection 156mg/kg ADP solution after 1 hour, the time of recovery of record righting reflex loss, the inhibition percentage of calculating effect.The results are shown in Table 2.
Table 2 ADP causes mouse brain embolism model
From above pharmacological evaluation, the platelet aggregation that compound of the present invention can obviously suppress ADP to induce.Therefore, they can be used for preventing or treating the coronary syndrome caused because of platelet aggregation, myocardial infarction, the cardiovascular and cerebrovascular diseases such as myocardial ischemia.
By the acute toxicity of animal experiment preliminary examinations the compounds of this invention.
Mouse oral chemical compounds I-1 ~ I-3 and clopidogrel 400mg/kg
-1d
-1after, carry out observing for one week to the general behavior of mouse after administration and body weight.Result shows, after mouse gives above-mentioned 3 compounds, heart rate, breathing and independent behaviour activity are showed no exception, observes Mouse Weight increase normal through one week body weight.Preliminary result shows the LD of oral administration of compound I-1, I-2 and clopidogrel
50be respectively 3400mg/kg, 3350mg/kg and 3200mg/kg, visible I-1 and I-2 toxicity is slightly lower than clopidogrel.
Embodiment
Below in conjunction with embodiment, the present invention is described further, and embodiment is only indicative, never means that it limits the scope of the invention by any way.Described compound is through high performance liquid chromatography (HPLC), and thin-layer chromatography (TLC) detects.Such as infrared spectra (IR) can be adopted subsequently, nuclear magnetic resonance spectrum (
1h NMR,
13c NMR), mass spectrum (MS) etc. further confirms its structure.
Reference example 1
The preparation of intermediate III-1
22.1g (0.01mol) 4-ethanoyl-1-cyclopropane-2 is added in the reaction flask that stirring, condenser, thermometer are housed; 5-dimethyl-1H-pyrroles-3-carboxylic acid (II); dissolved with 100ml thionyl chloride; stir, back flow reaction 4h (flaggy display reacts completely).By thionyl chloride evaporate to dryness, obtain white solid (HPLC:99.6%).HRMS(m/z)[M+H]
+：240.0793.
embodiment 1
The preparation of 1-(1-cyclopropyl-2,5-dimethyl-4-(thiazolidine-3-carbonyl)-1H-pyrroles-3-base) ethyl ketone (chemical compounds I-1)
In the reaction flask that stirring, condenser, thermometer are housed, add 24.0g (0.01mol) intermediate III-1, dissolved with 150ml methylene dichloride, under stirring, add triethylamine 20.2g (0.2mol).8.9g thiazolidine is added reaction system.Add, continue reaction 5h (flaggy display reacts completely) in backflow is lower.With 3 × 50ml water washing reaction solution, dichloromethane layer anhydrous sodium sulphate is fully dry, filter, methylene dichloride is to the greatest extent steamed in decompression, obtain faint yellow solid, post is separated [moving phase: v (sherwood oil): v (ethyl acetate)=1:2], can obtain white solid (HPLC:99.7%).HRMS(m/z)[M+H]
+：293.1279.
With reference to embodiment 1, can synthetic compound I-2 ~ I-3.
embodiment 2
Chemical compounds I-1 becomes hydrochloride: get I-1 white solid 2.9g, be dissolved in 15mL dehydrated alcohol.Ice-water bath is cooled to 5 DEG C, and dripping 11.1% ethanol solution hydrochloride to pH is 2, continues at stir about 1h under ice-water bath.Filter, obtain light yellow solid, vacuum-drying, m.p. > 230 DEG C.
embodiment 3
Chemical compounds I-2 becomes vitriol: get I-2 white solid 3.1g, be dissolved in 18mL acetone.Ice-water bath is cooled to 5 DEG C, and dripping 9.8% sulfuric acid acetone soln is 3 to pH, continues at stir about 1h under ice-water bath.Filter, obtain brown-red solid, vacuum-drying, m.p. > 230 DEG C.
embodiment 4
Chemical compounds I-3 becomes lactic acid salt: get I-3 white solid 3.1g, be dissolved in 20mL anhydrous methanol.To add etc. molar lactic acid after being heated to backflow, continue at stirred at reflux and react about 1h.React complete, in left at room temperature 24h.Separate out yellow crystal, filter, vacuum-drying, m.p. > 230 DEG C.
In order to the pharmaceutical composition of the oxime derivatives containing thienopyridine of the present invention is described more fully, provide following example of formulations below, described embodiment only for illustration of, instead of for limiting the scope of the invention.Described preparation can use any active compound in the compounds of this invention and salt thereof, preferably uses the compound described in embodiment 1-4.
embodiment 5
Hard gelatin capsule is prepared by following compositions:
Preparation technology: supplementary material is dry in advance, crosses 100 mesh sieves for subsequent use.After mentioned component being mixed by recipe quantity, be packed in hard gelatin capsule.
embodiment 6
Tablet is prepared by following compositions:
Preparation technology: supplementary material is dry in advance, crosses 100 mesh sieves for subsequent use.First the auxiliary material of recipe quantity is fully mixed.Be added in auxiliary material by bulk drug to increase progressively dilution method, each added-time fully mixes 2-3 time, ensures that medicine and auxiliary material fully mix, cross 20 mesh sieves, dry 2h in 55 DEG C of ventilated drying ovens, dry particle is crossed 16 mesh sieves and is arranged, measure intermediates content, mix, compressing tablet on tabletting machine.
embodiment 7
The preparation of injection liquid:
Preparation method: get activeconstituents and join in the water for injection dissolving sorbyl alcohol and propylene glycol, adds medicinal basic adjust ph to 4 ~ 8 and makes it dissolve.Add gac, whip attachment 30min, carbon removal, essence filter, embedding, sterilizing.
embodiment 8
The preparation of injection lyophilized powder:
Chemical compounds I-2 100mg
Medicinal basic 0.1-7.0%
N.F,USP MANNITOL 55-85%
Preparation method: get activeconstituents and add water for injection, makes it dissolve by medicinal basic adjust ph to 4-8.Add N.F,USP MANNITOL again, carry out autoclaving, add gac by the requirement of injection, adopt filtering with microporous membrane, filtrate carries out packing, adopts freeze-drying, and obtained loose block, sealing, to obtain final product.
Claims (9)
1. there is compound or its pharmacy acceptable salt of structure shown in formula I:
Wherein:
m＝0，1；
R is: hydrogen, methyl.
2. have compound or its pharmacy acceptable salt of structure shown in formula I as claimed in claim 1, described compound is:
3. have compound or its pharmacy acceptable salt of structure shown in formula I as claimed in claim 1, its pharmacy acceptable salt is: formula I and mineral acid, organic acid salify.
4. there is compound or its pharmacy acceptable salt of structure shown in formula I as claimed in claim 3; its pharmacy acceptable salt is: hydrochloride, hydrobromate, hydriodate, vitriol, hydrosulfate, phosphoric acid salt, acetate, propionic salt, butyrates, lactic acid salt, mesylate; tosilate, maleate, benzoate, succinate, tartrate, Citrate trianion, fumarate, taurate.
5. the preparation method of type I compound according to claim 1; it is characterized in that: 4-ethanoyl-1-cyclopropane-2; 5-dimethyl-1H-pyrroles-3-carboxylic acid II; in thionyl chloride solvent, the lower reaction of backflow generates key intermediate III, and intermediate III and compound 2 are at methylene dichloride, trichloromethane, acetone, N; in dinethylformamide or toluene solvant; under the catalysis of acid binding agent ,-10 ~ 30 DEG C of reacting generating compounds I
M, R are as claimed in claim 1.
6. preparation method as claimed in claim 5, described acid binding agent is triethylamine, pyridine, salt of wormwood, sodium carbonate, sodium bicarbonate, saleratus, sodium hydroxide, potassium hydroxide.
7. a pharmaceutical composition for platelet aggregation-against, comprises the compound of the structure shown in formula I described in any one of claim 1 ~ 2 for the treatment of significant quantity or its pharmacy acceptable salt and one or more pharmaceutical carriers.
8. the compound of the structure shown in formula I as described in any one of claim 1 ~ 2 or its pharmacy acceptable salt are for the preparation of the application in medicament for resisting platelet aggregation.
9. apply as claimed in claim 8, the purposes in the cardiovascular and cerebrovascular diseases medicament caused because of platelet aggregation for the preparation for the treatment of.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210301823.9A CN102796093B (en) | 2012-08-23 | 2012-08-23 | Thiomorpholine-containing pyrrole derivatives and their preparation method and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210301823.9A CN102796093B (en) | 2012-08-23 | 2012-08-23 | Thiomorpholine-containing pyrrole derivatives and their preparation method and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102796093A CN102796093A (en) | 2012-11-28 |
| CN102796093B true CN102796093B (en) | 2015-06-24 |
Family
ID=47195429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210301823.9A Active CN102796093B (en) | 2012-08-23 | 2012-08-23 | Thiomorpholine-containing pyrrole derivatives and their preparation method and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102796093B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106397356B (en) * | 2016-08-31 | 2019-08-13 | 郑州原理生物科技有限公司 | The preparation method of thiomorpholine -1,1- dioxide. HCl, the preparation method of thiomorpholine -1,1- dioxide |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0011373A1 (en) * | 1978-10-14 | 1980-05-28 | Beecham Group Plc | 5-Oxo-5H-hexahydrofuro(3,2-b)pyrrole derivatives, their preparation, intermediates, and pharmaceutical compositions containing said derivatives |
| CN101781311A (en) * | 2010-03-12 | 2010-07-21 | 天津药物研究院 | Novel preparation method of platelet aggregation inhibition compound |
| CN101812072A (en) * | 2010-05-27 | 2010-08-25 | 天津药物研究院 | Method for preparing anti-platelet aggregation compounds |
-
2012
- 2012-08-23 CN CN201210301823.9A patent/CN102796093B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0011373A1 (en) * | 1978-10-14 | 1980-05-28 | Beecham Group Plc | 5-Oxo-5H-hexahydrofuro(3,2-b)pyrrole derivatives, their preparation, intermediates, and pharmaceutical compositions containing said derivatives |
| CN101781311A (en) * | 2010-03-12 | 2010-07-21 | 天津药物研究院 | Novel preparation method of platelet aggregation inhibition compound |
| CN101812072A (en) * | 2010-05-27 | 2010-08-25 | 天津药物研究院 | Method for preparing anti-platelet aggregation compounds |
Non-Patent Citations (1)
| Title |
|---|
| 陈继方,等.氯吡格雷类似物的合成及其抗血小板聚集活性.《合成化学》.2010,第18卷(第5期),第586-590页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102796093A (en) | 2012-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101402641B (en) | Oxime derivatives containing thienopyridine, preparation method and application thereof | |
| CN1318428C (en) | Thiophenopyridine substituted acetyl hyarazine derivative | |
| CN101260112B (en) | Acethydrazide derivatives containing thieno[3.2-c]pyridine, preparation method and use thereof | |
| EP2570417B1 (en) | Thienopyridine ester derivative containing nitrile, preparation method, use and composition thereof | |
| JP2015232046A (en) | CRYSTALLINE FORM OF FACTOR Xa INHIBITOR | |
| JP2013536220A (en) | Methods for treating or preventing thrombosis or emboli | |
| CN104447867A (en) | Thienopiperidine derivative, preparation method and application thereof | |
| TWI784276B (en) | New uses of complexes of metabolites of angiotensin II receptor antagonists and NEP inhibitors | |
| CN101974015B (en) | Ester compound and preparation method and application thereof | |
| CN102351877B (en) | Thiophene derivative, its preparation method and its application | |
| CN102796093B (en) | Thiomorpholine-containing pyrrole derivatives and their preparation method and use | |
| CN102796040B (en) | 1,4-disubstituted piperazine derivatives and their preparation method and use | |
| JP2018520128A (en) | Deuterated thienopiperidine derivatives, methods of preparation, and uses thereof | |
| CN102268012B (en) | Thiazole derivative and preparation method and application thereof | |
| CN102838651B (en) | Oleanolic acid derivatives, and preparation method and application thereof | |
| EP3315493B1 (en) | Phenyl amino pyrimidine compound or polymorph of salt thereof | |
| CN101693718B (en) | Ester derivative containing thienopyridine and preparation method and application thereof | |
| CN101781310B (en) | Thiofuran-pyridine [3, 2-c] contained acethydrazide derivative and preparation method and application thereof | |
| CN102351878B (en) | Isoxazole derivatives as well as preparation method and application thereof | |
| CN103304561B (en) | One class has the compound of anti thrombotic action | |
| CN112778371B (en) | Thienopyridine derivative and preparation method and application thereof | |
| CN103864756A (en) | Butanedisulfonic acid dabigatran etexilate and preparation method and application thereof | |
| CN101830911A (en) | Thienopyridine derivatives, preparation method and application thereof | |
| WO2008142106A1 (en) | Salts of picotamide | |
| RU2526624C2 (en) | Thienopyridine ester derivative, containing cyanogroup, method of its obtaining, its application and based on it composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |